Life Sciences Daily Summary
Life Sciences Daily Summary: What Happened on October 31, 2026
FDA advisers back another trial for Sydnexis’ pediatric myopia drug
The panel questioned whether existing trial results show a meaningful benefit from low-dose atropine, despite the treatment meeting prespecified endpoints.
Today in brief
An FDA advisory panel favored another trial of Sydnexis’ low-dose atropine treatment for children with myopia.1
FDA advisers want more evidence for Sydnexis drug
The panel favored another trial to establish whether Sydnexis’ SYD-101 provides a meaningful benefit in pediatric myopia.1 The FDA had issued the company a complete response letter, citing inadequate evidence of effectiveness, although the lower dose met the Phase III STAR trial’s prespecified endpoints.1